{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T17:14:17Z","timestamp":1649092457233},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0152195","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T13:43:04Z","timestamp":1459431784000},"page":"e0152195","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis"],"prefix":"10.1371","volume":"11","author":[{"given":"Bo","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica M.","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesley","family":"Eddings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Landon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,3,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/pds.3312","article-title":"Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence","volume":"21","author":"AS Czaja","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.18553\/jmcp.2003.9.6.559","article-title":"Examination of the evidence for off-label use of gabapentin","volume":"9","author":"A Mack","year":"2003","journal-title":"J Managed Care Pharm"},{"key":"ref3","unstructured":"Agency for Healthcare Research and Quality. Off-label use of atypical antipsychotics: an update. Sept 2011. Available: http:\/\/www.effectivehealthcare.ahrq.gov\/ehc\/products\/150\/778\/CER43_Off-LabelAntipsychotics_20110928.pdf<\/ext-link>. Accessed 13 November 2014."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1377\/hlthaff.2011.0370","article-title":"False Claims Act prosecution did not deter off-label drug use in the case of Neurontin","volume":"30","author":"AS Kesselheim","year":"2011","journal-title":"Health Aff (Millwood)"},{"key":"ref5","unstructured":"US Food and Drug Administration. Drug Research and Children. Available: http:\/\/www.fda.gov\/Drugs\/ResourcesForYou\/Consumers\/ucm143565.htm<\/ext-link>. Accessed 14 November 2014."},{"key":"ref6","unstructured":"World Health Organization. Promoting safety of medicines for children. Available: http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/Promotion_safe_med_childrens.pdf<\/ext-link>. Accessed 14 November 2014."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pds.2082","article-title":"Increasing off-label use of antipsychotic medications in the United States, 1995\u20132008","volume":"20","author":"GC Alexander","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","article-title":"Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns","volume":"19","author":"B Vitiello","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.clinthera.2013.04.004","article-title":"Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications","volume":"35","author":"JA DiMasi","year":"2013","journal-title":"Clin Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/MLR.0b013e318245a160","article-title":"Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review","volume":"50","author":"SB Dusetzina","year":"2012","journal-title":"Med Care"},{"key":"ref11","first-page":"119","article-title":"ADHD medication use following FDA risk warnings","volume":"15","author":"CL Barry","year":"2012","journal-title":"J Ment Health Policy Econ"},{"key":"ref12","unstructured":"Eli Lilly and Company. FDA Approves Lilly\u2019s Zyprexa for Two Adolescent Indications. 2009. Available: https:\/\/investor.lilly.com\/releasedetail.cfm?releaseid=428395<\/ext-link>"},{"key":"ref13","unstructured":"AstraZeneca. US FDA Approves Seroquel For The Paediatric Treatment Of Schizophrenia And Bipolar Mania. 2009. Available: http:\/\/www.astrazeneca.com\/Media\/Press-releases\/Article\/20091203--US-FDA-Approves-Seroquel-For-The-Paediatric-Treatment<\/ext-link>"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.7326\/M13-2381","article-title":"Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction","volume":"161","author":"AS Kesselheim","year":"2014","journal-title":"Ann Intern Med"},{"key":"ref15","first-page":"S1","article-title":"Survey of disability, medication use, and medication satisfaction among members with rheumatoid arthritis of a large health care plan database","volume":"14","author":"PM Eng","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref16","unstructured":"Advisory meeting minutes: US Food and Drug Administration. Summary Minutes of the Psychopharmacologic Drugs Advisory Committee Meeting, June 9\u201310, 2009. Available: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/UCM197899.pdf<\/ext-link>. Accessed 13 November 2014"},{"key":"ref17","unstructured":"Pfizer. Geodon. 2013. Available: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020825s046,020919s030,021483s009lbl.pdf<\/ext-link>."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/10445460152595568","article-title":"A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder","volume":"11","author":"JA Frazier","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00004714-200210000-00003","article-title":"Open-label study of olanzapine in children with pervasive developmental disorder","volume":"22","author":"C Kemner","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 13","key":"ref20","first-page":"27","article-title":"Use of quetiapine in children and adolescents","volume":"63","author":"RL Findling","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1089\/cap.2004.14.471","article-title":"Ziprasidone monotherapy in pediatric bipolar disorder","volume":"14","author":"MS Barnett","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref22","unstructured":"US Department of Justice. Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa. 2009. Available: http:\/\/www.justice.gov\/archive\/opa\/pr\/2009\/January\/09-civ-038.html<\/ext-link>."},{"key":"ref23","unstructured":"US Department of Justice. Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-label Drug Marketing. 2010. Available: http:\/\/www.justice.gov\/opa\/pr\/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing<\/ext-link>. Accessed 13 November 2014."},{"key":"ref24","unstructured":"US Department of Justice. Justice Department Announces Largest Health Care Fraud Settlement in Its History. 2009. Available: http:\/\/www.justice.gov\/opa\/pr\/justice-department-announces-largest-health-care-fraud-settlement-its-history<\/ext-link>. Accessed 13 November 2014"},{"key":"ref25","unstructured":"Harris G and Berenson A. Lilly said to be near $1.4 billion U.S. settlement. New York Times, 14 January 2009. Available: http:\/\/www.nytimes.com\/2009\/01\/15\/business\/15drug.html<\/ext-link>. Accessed 13 November 2014"},{"key":"ref26","unstructured":"Harris G. Pfizer pays $2.3 billion to settle marketing case. New York Times, 2 September 2009. Available: http:\/\/www.nytimes.com\/2009\/09\/03\/business\/03health.html<\/ext-link>. Accessed 13 November 2014."},{"key":"ref27","unstructured":"Wilson D. For $520 million, AstraZeneca will settle case over marketing of a drug. 26 April 2010. Available: http:\/\/www.nytimes.com\/2010\/04\/27\/business\/27drug.html<\/ext-link>. Accessed 13 November 2014."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"CU Correll","year":"2009","journal-title":"JAMA"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archpedi.162.10.929","article-title":"Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents","volume":"162","author":"RS McIntyre","year":"2008","journal-title":"Arch Pediatr Adolesc Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/bmj.38330.470486.8F","article-title":"Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study","volume":"330","author":"SS Gill","year":"2005","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs. atypical antipsychotic medications","volume":"353","author":"PS Wang","year":"2005","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/aje\/kwj289","article-title":"Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia","volume":"164","author":"BL Lambert","year":"2006","journal-title":"Am J Epidemiol"},{"key":"ref33","unstructured":"Tarkan L. Doctors say medication is overused in dementia. New York Times. 24 June 2008. Available: http:\/\/www.nytimes.com\/2008\/06\/24\/health\/24deme.html?pagewanted=all<\/ext-link>. Accessed 13 November 2014"},{"key":"ref34","unstructured":"US Food and Drug Administration. Approval Letter. Available: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2007\/021436s017,%20021713s012,%20021729s004,%20021866s004ltr.pdf<\/ext-link>. Accessed 30 December 2014."},{"key":"ref35","unstructured":"US Food and Drug Administration. Approval Letter. Available: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2008\/021436s021,%20021713s016,%20021729s008,%20021866s008ltr.pdf<\/ext-link>. Accessed 30 December 2014."},{"key":"ref36","unstructured":"US Food and Drug Administration. Approval Letter. Available: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2007\/020272s46s47,20588s36s37,21444s20s21ltr.pdf<\/ext-link>. Accessed 30 December 2014."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1542\/peds.2009-1288","article-title":"Pediatric uptake of a newly available antipsychotic medication","volume":"125","author":"RB Penfold","year":"2010","journal-title":"Pediatrics"},{"key":"ref38","unstructured":"FDA approves Geodon for bipolar disorder. Bipolar Disorder Daily News Blog. Available: http:\/\/www.pendulum.org\/bpnews\/archive\/001976.html<\/ext-link>. Accessed 30 December 2014."},{"key":"ref39","unstructured":"Boehringer Ingelheim Pharmaceuticals. Jardiance. 2014. Available: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204629s000lbl.pdf<\/ext-link>. Accessed 13 November 2014."},{"key":"ref40","unstructured":"Boehringer Ingelheim Pharmaceuticals. Striverdi Respimat. 2014. Available: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/203108s000lbl.pdf<\/ext-link>. Accessed 13 November 2014."},{"key":"ref41","unstructured":"Paladin Therapeutics. Impavido. 2014. Available: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204684s000lbl.pdf<\/ext-link>. Accessed 13 November 2014."},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1001\/jamainternmed.2014.5266","article-title":"Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels","volume":"174","author":"B Wang","year":"2014","journal-title":"JAMA Intern Med"},{"key":"ref43","unstructured":"Department of Health and Human Services and US Food and Drug Administration. FDA transparency initiative: improving transparency to regulated industry. http:\/\/www.fda.gov\/downloads\/AboutFDA\/Transparency\/TransparencytoRegulatedIndustry\/PhaseIIITransparencyReport\/UCM239088.pdf<\/ext-link>. Accessed 13 November 2014."},{"key":"ref44","unstructured":"Department of Health and Human Services and US Food and Drug Administration. FDA transparency initiative: improving transparency to regulated industry. http:\/\/www.fda.gov\/downloads\/AboutFDA\/Transparency\/TransparencytoRegulatedIndustry\/PhaseIIITransparencyReport\/UCM239088.pdf<\/ext-link>. Accessed 13 November 2014."},{"key":"ref45","unstructured":"Department of Health and Human Services and US Food and Drug Administration. Food and Drug Administration transparency initiative: increasing public access to FDA\u2019s compliance and enforcement data. Available: http:\/\/www.fda.gov\/downloads\/AboutFDA\/Transparency\/TransparencyReports\/UCM394213.pdf<\/ext-link>. Accessed 13 November 2014."},{"key":"ref46","unstructured":"Food and Drug Administration. Clinical review: submission number 20-825\/S-032. Available: http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM193490.pdf<\/ext-link>. Accessed 13 November 2014."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0152195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T08:21:21Z","timestamp":1540282881000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0152195"}},"subtitle":[],"editor":[{"given":"Dermot","family":"Cox","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0152195","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,31]]}}}